Protection assessments indicated that gastrointestinal adverse events, mostly nausea and diarrhea, were dose-dependent but normally mild and transient. These findings established the therapeutic window and knowledgeable dose collection for subsequent Stage three trials.“Noom built the process so uncomplicated and now I really feel comprehensive,